John B. Amos Cancer Center at Piedmont Columbus Regional ’s midtown medical complex is the first in Georgia to offer this ...

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuster ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing ... Novartis removed one other drug from its pipeline this morning in the form of ...

A thyroglobulin antibody (TgAb) test looks for certain antibodies that attack the thyroid. The presence of TbAb in high levels may indicate that someone has an autoimmune condition. To conduct a ...

Click here to read more @ c-MET-NSCLC Pipeline Outlook JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations ...

Genmab has established itself as a leader in the development of antibody therapeutics ... Key developments in Genmab's pipeline include: 1. Epkinly: This recently launched product has shown promising ...

Genmab A/S (NASDAQ:GMAB), a Danish biotechnology company specializing in antibody therapeutics for ... of approved medicines and a promising pipeline, the company faces both significant ...